Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial

Neurology

Volumn 64, Issue 4, 2005, Pages 713-715

  Sândor, Peter S ^a   Di Clemente, L ^c   Coppola, G ^c   Saenger, U ^a,b   Fumal, A ^c   Magis, D ^c   Seidel, L ^d   Agosti, R M ^a,b   Schoenen, J ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Headache Centre Zurich Hirslanden   (Switzerland)

^c Centre Hospitalier Regional de La Citadelle   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIBOFLAVIN; UBIDECARENONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENERGY METABOLISM; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 13844316604     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000151975.03598.ED     Document Type: Article

References (10)

1. Welch KMA, Levine SR, D'Andrea G, Schultz L, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31phosphorus NMR spectroscopy. Neurology 1989;39:538-541.
2. Watanabe H, Kuwabara T, Ohkubo M, Tsuji S, Yuasa T. Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996;47:1093-1095.
3. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu (UTIR) mutation: correlation of clinical state, nerve conduction, and muscle 3 IP magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-2152.
4. Nishikawa Y, Takahashi M, Yorifuji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 1989;39:399-403.
5. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466-470.
6. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-141.
7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1-96.
8. International Headache Society Committee on Clinical trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st ed. Cephalagia 1991;11:1-12.
9. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999;83:147-156.
10. Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH. Adsorption tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinson patients. Neurology 1998;50:793-795.